



Anti-tubercular activity and molecular docking studies of indolizine derivatives targeting mycobacterial InhA enzyme

Katharigatta N. Venugopala, Sandeep Chandrashekhara, Pran Kishore Deb, Christophe Tratat, Melendhran Pillay, Deepak Chopra, Nizar A. Al-Shar'i, Wafa Hourani, Lina A. Dahabiyeh, Pobitra Borah, Rahul D. Nagdeve, Susanta K. Nayak, Basavaraj Padmashali, Mohamed A. Morsy, Bandar E. Aldhubiab, Mahesh Attimarad, Anroop B. Nair, Nagaraja Sreeharsha, Michelyne Haroun, Sheena Shashikanth, Viresh Mohanlall & Raghuprasad Mailavaram

To cite this article: Katharigatta N. Venugopala, Sandeep Chandrashekhara, Pran Kishore Deb, Christophe Tratat, Melendhran Pillay, Deepak Chopra, Nizar A. Al-Shar'i, Wafa Hourani, Lina A. Dahabiyeh, Pobitra Borah, Rahul D. Nagdeve, Susanta K. Nayak, Basavaraj Padmashali, Mohamed A. Morsy, Bandar E. Aldhubiab, Mahesh Attimarad, Anroop B. Nair, Nagaraja Sreeharsha, Michelyne Haroun, Sheena Shashikanth, Viresh Mohanlall & Raghuprasad Mailavaram (2021) Anti-tubercular activity and molecular docking studies of indolizine derivatives targeting mycobacterial InhA enzyme, *Journal of Enzyme Inhibition and Medicinal Chemistry*, 36:1, 1472-1487, DOI: [10.1080/14756366.2021.1919889](https://doi.org/10.1080/14756366.2021.1919889)

To link to this article: <https://doi.org/10.1080/14756366.2021.1919889>



© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.



[View supplementary material](#)



Published online: 01 Jul 2021.



[Submit your article to this journal](#)



Article views: 343



[View related articles](#)










View Crossmark data [↗](#)

RESEARCH PAPER



Anti-tubercular activity and molecular docking studies of indolizine derivatives targeting mycobacterial InhA enzyme

Katharigatta N. Venugopala^{a,b} , Sandeep Chandrashekarappa^c, Pran Kishore Deb^d , Christophe Tratat^a, Melendhran Pillay^e, Deepak Chopra^f, Nizar A. Al-Shar'i^g , Wafa Hourani^d, Lina A. Dahabiyeh^h , Pobitra Borahⁱ, Rahul D. Nagdeve^j, Susanta K. Nayak^j, Basavaraj Padmashali^k, Mohamed A. Morsy^{a,l}, Bandar E. Aldhubiab^a , Mahesh Attimarad^a, Anroop B. Nair^a , Nagaraja Sreeharsha^{a,m}, Michelyne Haroun^a, Sheena Shashikanthⁿ, Viresh Mohanlal^b and Raghuprasad Mailavaram^o 

^aDepartment of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa, Saudi Arabia; ^bDepartment of Biotechnology and Food Technology, Durban University of Technology, Durban, South Africa; ^cInstitute for Stem Cell Science and Regenerative Medicine (inStem), Bangalore, India; ^dFaculty of Pharmacy, Department of Pharmaceutical Sciences, Philadelphia University, Amman, Jordan; ^eDepartment of Microbiology, National Health Laboratory Services, KZN Academic Complex, Inkosi Albert Luthuli Central Hospital, Durban, South Africa; ^fDepartment of Chemistry, Indian Institute of Science Education and Research Bhopal, Bhopal, India; ^gFaculty of Pharmacy, Department of Medicinal Chemistry and Pharmacognosy, Jordan University of Science and Technology, Irbid, Jordan; ^hDepartment of Pharmaceutical Sciences, School of Pharmacy, The University of Jordan, Amman, Jordan; ⁱPratiksha Institute of Pharmaceutical Sciences, Guwahati, India; ^jDepartment of Chemistry, Visvesvaraya National Institute of Technology, Nagpur, India; ^kDepartment of Chemistry, School of Basic Science, Rani Channamma University, Belagavi, India; ^lFaculty of Medicine, Department of Pharmacology, Minia University, El-Minia, Egypt; ^mDepartment of Pharmaceutics, Vidya Siri College of Pharmacy, Bangalore, India; ⁿDepartment of Studies in Organic Chemistry, University of Mysore, Mysore, India; ^oPharmaceutical Chemistry Division, Sri Vishnu College of Pharmacy, Bhimavaram, India

ABSTRACT

A series of 1,2,3-trisubstituted indolizines (**2a–2f**, **3a–3d**, and **4a–4c**) were screened for *in vitro* whole-cell anti-tubercular activity against the susceptible H37Rv and multidrug-resistant (MDR) *Mycobacterium tuberculosis* (MTB) strains. Compounds **2b–2d**, **3a–3d**, and **4a–4c** were active against the H37Rv-MTB strain with minimum inhibitory concentration (MIC) ranging from 4 to 32 µg/mL, whereas the indolizines **4a–4c**, with ethyl ester group at the 4-position of the benzoyl ring also exhibited anti-MDR-MTB activity (MIC = 16–64 µg/mL). *In silico* docking study revealed the enoyl-acyl carrier protein reductase (InhA) and anthranilate phosphoribosyltransferase as potential molecular targets for the indolizines. The X-ray diffraction analysis of the compound **4b** was also carried out. Further, a safety study (*in silico* and *in vitro*) demonstrated no toxicity for these compounds. Thus, the indolizines warrant further development and may represent a novel promising class of InhA inhibitors and multi-targeting agents to combat drug-sensitive and drug-resistant MTB strains.

ARTICLE HISTORY

Received 29 December 2020
Revised 9 April 2021
Accepted 12 April 2021

KEYWORDS

Indolizine; mycobacterium tuberculosis; InhA; docking; X-ray crystal structure


1. Introduction

Tuberculosis (TB) is a communicable infectious disease and a major cause of illness, particularly in low-income countries. It is caused by the opportunistic bacillus *Mycobacterium tuberculosis* (MTB) which primarily attacks the lungs (pulmonary) but may later affect other parts (extra-pulmonary) of the body¹. According to the World Health Organisation (WHO), TB is considered as one of the top 10 causes of death worldwide, and the leading cause of death from a single infectious agent¹. In 2019, TB resulted in nearly 1.4 million deaths, including 208,000 deaths among human immunodeficiency virus (HIV) positive patients². HIV-infected patients are 19 times more likely to develop TB than HIV-negative subjects^{3,4}. Several factors have contributed to the continuous health threat of TB globally. This includes the development of drug resistance such as multidrug-resistant tuberculosis (MDR-TB), extensively drug-resistant tuberculosis (XDR-TB)⁵, and totally drug-

resistant tuberculosis (TDR-TB)⁶; the co-morbidities with acquired immunodeficiency syndrome (AIDS)^{7,8} and the risks involved in developing diabetes mellitus among TB patients^{9,10}.

Several therapeutics have been approved by the US Food and Drug Administration (US-FDA) to enhance the treatment of TB. Bedaquiline (approved in late 2012 under the FDA's accelerated review program) (Figure 1) was found to exhibit favourable anti-TB effects and promising anti-TB action against MDR and XDR-TB when combined with first-line or second-line anti-TB drugs, resulting in a shorter duration of treatment. However, bedaquiline suffered from various adverse effects such as nausea, elongation of QT interval, and drug interaction with Cytochrome P3A4 inducers and inhibitors¹¹. Delamanid (Figure 1) was the second anti-TB agent approved by European Medicine Agency in late 2013. Nevertheless, resistant MTB strains against both bedaquiline and delamanid have recently been reported, which acquired resistance

CONTACT Katharigatta N. Venugopala  kvenugopala@kfu.edu.sa  Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia; Pran Kishore Deb  prankishore1@gmail.com  Department of Pharmaceutical Sciences, Philadelphia University, Amman 19392, Jordan

 Supplemental data for this article can be accessed [here](#).

© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.




Figure 1. Chemical structures of approved anti-TB drugs (Bedaquiline, Delamanid and Pretomanid) and anti-TB compounds undergoing clinical trial (Q203, TBA-7371 and SQ109).

as a result of prolonged duration of therapy^{12,13}. Pretomanid was the last drug candidate from the TB drug pipeline to be approved by the FDA in 2019 for the treatment of MDR and XDR TB (Figure 1)^{14,15}.

For more than 40 years, there has been no significant active research in the arena of anti-TB drug discovery despite the fact that currently available drugs are considered cytotoxic and have low efficacy due to the emergence of resistant bacterial strains¹⁶. A recent call for the development of novel potential therapeutic agents to overcome MDR, XDR and TDR-TB have led to the discovery of a limited number of anti-TB drug candidates¹⁷. Among them, TBA-7371 (an azaindole) and Q203 or telacebac (an imidazopyridine amide) are very promising drug candidates for the potential treatment of MDR and XDR TB (Figure 1). However, considering the high attrition rate of drug candidates during clinical development, there is an urgent need to intensify and broaden the scope of the search for novel anti-TB lead structures by utilising validated new mycobacterial drug targets besides those targeted by current anti-TB therapies. A promising emerging approach to overcome MDR-TB is the development of multi-targeting compounds in which a single molecule has the ability to bind to different biological targets¹⁸. This concept is known as polypharmacology and has been proven promising in terms of efficacy, synergistic effect, and adverse events, and in preventing both drug-drug interaction and resistance insurgence¹⁸. For instance, SQ109, a drug candidate in the TB drug development pipeline, exhibits its anti-TB activity by acting on multiple targets (Figure 1). SQ109 is a well-known MmpL3 inhibitor that also shows inhibitory activity against MenA and MenG MTB enzymes as well¹⁹. It is worth mentioning that recently several natural products have also been reported as lead molecules against clinical MDR strains of MTB²⁰. Therefore, the discovery of

novel chemical entities having multiple modes of action is of paramount importance in the treatment of MDR, XDR, and TDR-TB infections.

This study stems from our interest in designing new potential anti-TB therapeutics by focussing on structural modifications of the indolizine scaffold which has demonstrated potential antimycobacterial activity as previously reported by our group^{21–23} and other researchers^{24–27}. Previously, we identified a series of poly-substituted indolizine A²¹, B²², and C²³ as promising anti-TB agents against MDR-TB (Figure 2). Based on our previously reported structure-activity relationship (SAR), the nature and the position of substituents on the indolizine scaffold were found to be very sensitive to retain the anti-mycobacterial activity against susceptible MTB strain as well as rifampicin and isoniazid-resistant clinical isolates of MTB. Approximately, two-thirds of the synthesised indolizines A, B, and C displayed moderate to good potency against susceptible H37Rv MTB strain, whilst half of the active derivatives demonstrated good inhibitory activity against MDR-MTB strain. Indolizine represents a privileged scaffold for the development of bioactive compounds. Several synthetic indolizines have also been reported to possess a broad spectrum of pharmacological activities such as analgesic, anti-inflammatory, anticancer, antidiabetic, antihistaminic, COX-2 inhibition, antileishmanic, antimicrobial, antitumagenic, antioxidant, antiviral, larvicidal, herbicidal and $\alpha 7$ nAChR inhibitors, anti-Alzheimer, anti-schizophrenic, anticonvulsant and inhibitors of various enzymes^{28–30}.

Despite the structural resemblance in the main bicyclic core of our designed compounds with Q203 and TBA-7371, to date, no indolizine-based anti-TB drug candidates have entered preclinical trials. With regards to the above considerations and as part of our continuous interest in the discovery of new potential anti-TB




Figure 2. Indolizine structures with anti-TB activity developed by our group.

drugs^{31–41} we report herein the anti-mycobacterial activity of a series of 1,2,3-trisubstituted indolizines of type **D** with the aim of expanding the current knowledge on our previously reported SAR by exploring the influence of substituents at 1, 2 and 3-position of the indolizine scaffold that might play a critical role in the anti-TB activity against H37Rv strain ATCC 25177 and MDR strains of MTB. Furthermore, the potential mechanism of action of the title compounds is suggested based on their anti-tubercular profile in parallel with the molecular modelling analyses. In addition, the ADMET and toxicity characteristics of the most promising indolizines are also presented.

2. Materials and methods

2.1. Chemistry

The chemicals reported here were obtained from Sigma-Aldrich Co. (St. Louis, MO, USA), while the solvents were obtained from Millipore Sigma (Burlington, MA, USA). Thin-layer chromatography (TLC) using silica gel (Sigma-Aldrich Co.) on aluminium foil was employed to observe the chemical reactions; *n*-hexane and ethyl acetate (4:6) were used as solvents. The reactions were visualised under an ultra-violet (UV)-light/iodine chamber. B-545 was used to measure the melting points (Büchi, Labortechnik, Flawil, Switzerland). Fourier-transform infrared (FT-IR) spectra were recorded on a Shimadzu FT-IR spectrophotometer. Furthermore, ¹H- and ¹³C-NMR spectra were recorded on Bruker AVANCE III 400 MHz instruments using DMSO-*d*₆ as a solvent. Chemical shifts (δ) were recorded in parts per million (ppm) downfield from tetramethylsilane, while the coupling constants (*J*) were recorded in Hz. The splitting pattern was documented as follows: s, singlet; d, doublet; q, quartet; m, multiplet. Liquid chromatography–mass spectrometry (LC–MS; Agilent 1100 series) was used to measure the mass spectra in conjunction with the MSD, as well as 0.1% aqueous trifluoroacetic acid in an acetonitrile system on the C18-BDS column. Then, elemental analysis was carried out using the analyser FLASH EA 1112 CHN (Thermo Finnigan LLC, New York, NY, USA). A single-crystal X-ray diffraction study was performed using a Bruker KAPPA APEX II DUO diffractometer equipped with a CCD detector; monochromated Mo K α radiation (λ = 0.71073 Å) was used. Data collection was carried out at 173(2) K using an Oxford Cryostream cooling system featuring the Bruker Apex II software.

2.1.1. General synthetic procedure for the preparation of 1-(2-(substitutedphenyl)-2-oxoethyl)pyridin-1-ium bromides (**1a–f**) and ethyl 3-(substitutedbenzoyl)-2-methylindolizine-1-carboxylates (**2a–2f** and **3a–3d**)

Compounds **1a–1f**, **2a–2f**, and **3a–3d** were synthesised, purified by column chromatography, and well characterised by FT-IR, NMR,

LC-MS, and elemental analysis as reported earlier from our research group⁴². The purity of the compounds was $\geq 99\%$ as measured by HPLC.

2.1.2. General procedure for the preparation of diethyl-3-(4-substitutedbenzoyl)indolizine-1,2-dicarboxylates (**4a–4c**)

To a stirred solution of 1-(2-(4-fluoro/chloro/nitro-phenyl)-2-oxoethyl)pyridin-1-ium bromide (**1a/1b/1d**) (0.0016 mol), in water (10 mL), was added substituted diethyl 2-butynedioate (0.0016 mol), stirred at 80 °C for 3 h. Completion of reaction was monitored on TLC. The reaction mixture was diluted with ethyl acetate. The organic layer was separated, washed with brine and dried under sodium sulphate. The crude compound was purified by recrystallization method using hexane and ethyl acetate to afford 69–83% yield of diethyl-3-(4-substitutedbenzoyl)indolizine-1,2-dicarboxylate (**4a–4c**). The characterisation details of title compounds (**4a–4c**) are reported below, and their spectral data are shown in Figures S1–S9.

2.1.2.1. Diethyl-3-(4-fluorobenzoyl)indolizine-1,2-dicarboxylate (**4a**).

Appearance; Brown solid. Yield 72%, MP 138–139, FT-IR (KBr neat cm^{-1}): 2985, 1733, 1695, 1635, 1608, 1228. ¹H NMR (400 MHz, CDCl₃) δ = 9.51–9.48 (d, *J* = 7.2 Hz, 1H), 7.78–7.70 (m, 3H), 7.16–7.11 (m, 2H), 6.82–6.77 (m, 1H), 4.36–4.30 (q, *J* = 7.2 Hz, 2H), 3.76–3.68 (q, *J* = 7.2 Hz, 2H), 1.37–1.33 (t, *J* = 7.2 Hz, 3H), 1.13–1.11 (t, *J* = 7.2 Hz, 3H). ¹³C-NMR (100 MHz CDCl₃) δ = 183.77, 165.17, 164.12, 163.62, 163.23, 159.92, 141.51, 136.09, 136.02, 132.21, 131.59, 131.23, 129.89, 119.59, 115.62, 114.87, 110.18, 102.38, 97.63, 61.66, 60.28, 55.87, 14.32, 13.52. LC-MS (ESI, Positive): *m/z*: (*M* + *H*)⁺: 384.38: Anal. calculated for: C₂₁H₁₈FNO₅; C, 65.79; H, 4.73; N, 3.65; Found; C, 65.41; H, 4.50; N, 3.55.

2.1.2.2. Diethyl-3-(4-chlorobenzoyl)indolizine-1,2-dicarboxylate (**4b**).

Appearance; Brown solid. Yield 74%, MP 137–138, FT-IR (KBr neat cm^{-1}): 2989, 1736, 1696, 1637, 1605, 1227. ¹H NMR (400 MHz, CDCl₃) δ = 9.53–9.49 (d, *J* = 7.2 Hz, 1H), 7.76–7.71 (m, 3H), 7.15–7.10 (m, 2H), 6.82–6.77 (m, 1H), 4.37–4.30 (q, *J* = 7.2 Hz, 2H), 3.72–3.68 (q, *J* = 7.2 Hz, 2H), 1.37–1.33 (t, *J* = 7.2 Hz, 3H), 1.13–1.10 (t, *J* = 7.2 Hz, 3H). ¹³C-NMR (100 MHz CDCl₃) δ = 183.51, 165.34, 164.15, 163.59, 163.30, 160.21, 141.49, 136.07, 135.89, 132.23, 131.28, 131.16, 129.91, 119.48, 115.49, 114.99, 110.24, 102.74, 97.69, 61.78, 60.36, 55.71, 14.42, 13.83. LC-MS (ESI, Positive): *m/z*: (*M* + *H*)⁺: 400.2: Anal. calculated for: C₂₁H₁₈ClNO₂; C, 63.09; H, 4.54; N, 3.50; Found; C, 62.91; H, 4.48; N, 3.45.

2.1.2.3. Diethyl-3-(4-nitrobenzoyl)indolizine-1,2-dicarboxylate (**4c**).

Appearance; Light green colour. Yield 70%, MP 111–112, FT-IR

(KBr neat cm^{-1}): 2983, 1739, 1700, 1649, 1603, 1225. $^1\text{H-NMR}$ (400 MHz CDCl_3) δ = 9.49–9.47 (d, J = 7.2 Hz, 1H), 7.77–7.72 (m, 3H), 7.15–7.11 (m, 2H), 6.81–6.78 (m, 1H), 4.38–4.32 (q, J = 7.2 Hz, 2H), 3.75–3.69 (q, J = 7.2 Hz, 2H), 1.36–1.33 (t, J = 7.2 Hz, 3H), 1.13–1.11 (t, J = 7.2 Hz, 3H). $^{13}\text{C-NMR}$ (100 MHz CDCl_3) δ = 184.77, 166.12, 165.08, 163.59, 163.29, 159.91, 142.47, 137.04, 136.03, 132.21, 131.25, 131.18, 129.95, 119.52, 116.59, 114.93, 109.15, 103.44, 98.59, 61.58, 60.29, 55.87, 14.31, 13.72. LC-MS (ESI, Positive): m/z : $(\text{M} + \text{H})^+$: 411.2; Anal. calculated for: $\text{C}_{21}\text{H}_{18}\text{N}_2\text{O}_7$; C, 61.46; H, 4.42; N, 6.83; Found; C, 61.31; H, 4.30; N, 6.55.

2.2. Crystallography

Single-crystal X-ray diffraction data of the compound **4b** was collected on a Bruker KAPPA APEX II DUO diffractometer using graphite-monochromated Mo-K α radiation (λ = 0.71073 Å). Data collection⁴³ was carried out at 173(2) K. Temperature was controlled by an Oxford Cryostream cooling system (Oxford Cryostat). Cell refinement and data reduction were performed using the SAINT program⁴⁴. The data were scaled and absorption correction was performed using SADABS⁴⁴.

The structure was solved by direct methods using SHELXS-97⁴⁵ and refined by the full-matrix least-squares method based on F^2 using SHELXL-2014⁴⁶. All non-hydrogen atoms were refined anisotropically. All hydrogen atoms, were placed in idealised positions and refined in riding models with U_{iso} assigned 1.2 or 1.5 times the U_{eq} of their parent atoms, and the C–H bond distances were constrained to 0.95 Å for aromatic hydrogens and 1.00 Å for methylene and methyl hydrogens. All geometrical calculations were done using PLATON⁴⁷. The program WinGx⁴⁸ was used to prepare molecular graphic images.

2.3. Hirshfeld surface analysis and energy framework calculation

The Hirshfeld surfaces analysis is a technique for visualisation and investigation to illustrate the nature of intermolecular interactions. The Hirshfeld surfaces and two-dimensional fingerprint plot for compound **4b** have been generated using the software *Crystal Explorer 17.5*. This software has been also used to assess the interaction energies of the compound **4b**.

2.4. Anti-tubercular activity

The antitubercular activity of the designed compounds **2a–2f**, **3a–3d**, and **4a–4c** were evaluated against two types of MTB strains, namely H37Rv and well characterised MDR strains using the colorimetric Resazurin Microplate Assay (REMA) method⁴⁹. A 100 μL of Middlebrook 7H9 broth was aseptically prepared and dispensed in each of the wells of a 96 well flat-bottomed microtiter plate with lids (Lasec, South Africa). Each of the test compounds was accurately weighed, dissolved in the appropriate solvent, and filter sterilised using a 0.2 micron polycarbonate filter. Stock solutions of the test samples were aliquoted into cryovials and stored at -20°C . A 100 μL of the test samples were added to each of the wells containing Middlebrook 7H9 broth supplemented with 0.1% Casitone, 0.5% glycerol, and 10% OADC (oleic acid, albumin, dextrose, and catalase). The test samples were then serially diluted two folds directly in the broth of the microtiter plate to the desired concentration ranging from 40–0.625 $\mu\text{g/mL}$.

Inoculums from clinical isolates were prepared fresh from Middlebrook 7H11 agar plates by scraping and re-suspending

loopful of colonies into Middlebrook 7H9 broth containing glass beads. The inoculum turbidity was adjusted to a McFarland number 1 standard and further diluted to 1:10 in M7H9 broth prior to the addition of 100 μL to each of the test samples and drug-free wells. Growth control and a sterile control were also included for each isolate. Sterile M7H9 broth was added to all perimeter walls to avoid evaporation during the incubation. The plate was covered, sealed in a plastic bag, and incubated at 37°C . After 8 days of incubation, 30 μL of 0.02% working solution of resazurin salt was inoculated into each microtiter well. The plates were then incubated overnight and read the following day. A positive reaction resulted in a colour change from blue to pink owing to the reduction of resazurin to rezarufin which confirmed MTB cell viability/growth and, hence, drug resistance. The MICs were defined as the minimum drug concentration to inhibit the growth of the organism with no colour changes present in the well.

2.5. Safety studies (in vitro)

The safety of the tested indolizines was evaluated by MTT assay. The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) cytotoxicity assay was used to evaluate the cytotoxic effect of the most promising compounds against peripheral blood mononuclear cells (PBMCs) according to the described protocol⁵⁰. Cells were pipetted (90 μL of cell culture, 1×10^5 cells/mL) into each well of 96-well microtiter plates, and the outer wells were filled with PBS (phosphate buffer saline) in order to prevent the medium from evaporation during incubation. Thereafter, plates were incubated at 37°C for 24 h. Each well of the plate was then treated with 10 μL of the compounds (1000–5 $\mu\text{g/mL}$). In the control wells, the negative control DMSO (dimethyl sulfoxide) and media were added. Thereafter, the plates were incubated for 2 days at 37°C in a humidified incubator that contained a 5% CO_2 atmosphere. After the incubation time, 20 μL of MTT reagent (5 mg/mL) was further added to the individual well. The plate was then incubated for a further 4 h at 37°C (5% CO_2 incubator). The media was then removed, and an aliquot of 100 μL DMSO was added to each well in order to dissolve the formazan crystals that were formed in metabolically active cells. After that, plates were incubated for an extra hour. The absorbance of the formazan was evaluated at 590 nm using an ELISA plate reader (Thermo Scientific Multiskan GO).

2.6. Molecular modelling

Molecular docking of the designed compounds into the active site of proposed potential targets was performed using Accelrys Discovery Studio 4.0 (from BIOVIA Software Inc.). The X-ray crystal structures of mycobacterial enoyl-ACP-reductase (InhA) and anthranilate phosphoribosyltransferase (trpD) enzymes in complex with their inhibitors (PDB accession codes 5G0S and 3R6C, respectively) were retrieved from the RSCB Protein Data Bank.

Crystal complexes were prepared using the clean protein tool and prepare protein protocol in DS to standardise atoms names, correct connectivity and bond order, protonate the ionisable residues at a pH of 7.4, add missing residues and correct incomplete ones, and remove water molecules. To validate the docking protocol, the co-crystallised ligand was extracted and re-docked into the active site of the enzyme to ensure proper definition of the binding site and to assess the accuracy of the docking algorithm in reproducing the pose of the co-crystallised ligand. C-Docker protocol was used to perform the docking studies of the tested indolizines into their potential targets. The ligands are docked

into a rigid receptor while a set of ligand conformation is generated. Additional scoring functions PLP1, PLP2, Jain, and PMF were utilised to ensure the optimal ligand orientation into the active binding site of the target. The highest negative score of PLP1, PLP2, Jain, and PMF^{51,52}, indicating the strongest receptor-ligand binding affinities, is considered for refining binding poses. The binding energy calculation was performed using C-Docker protocol and *in situ* ligand minimisation protocol.

2.7. ADMET calculation (in silico)

The ADMET Descriptors protocol and the Toxicity Prediction (TOPKAT) protocol in DS were used to calculate a range of absorption, distribution, metabolism, excretion, and toxicity (ADMET) related properties including, aqueous solubility (AS), blood-brain barrier (BBB) penetration, CYP2D6 inhibition, hepatotoxicity, human intestinal absorption (HIA), plasma protein binding (PPB), AlogP, and polar surface area (PSA); in addition, different toxicity parameters including rodent carcinogenicity (for both male and female rats and mice, CMR, CFR, CLM and CFM respectively), Ames mutagenicity (AM), skin irritation (SI), ocular irritancy (OI), aerobic biodegradability and developmental toxicity potential (AB) were also calculated.

3. Results and discussion

3.1. Chemistry


The synthesis of the title compounds (**2a–2f**, **3a–3d**, **4a–4c**) is portrayed in Scheme 1. The intermediates (**1a–1f**) were obtained by stirring a mixture of pyridine, and para-substituted phenacyl bromides in a dry acetone medium at 5 h. Compounds **1a–1f** on further reaction with ethyl prop-2-ynoate/ethyl but-2-ynoate/diethyl

2-butyndioate in the presence of water with continuous stirring at 80 °C for 3 h resulted in the formation of title compounds **2a–2f**, **3a–3d**, **4a–4c**. The resulting title compounds were purified using ethyl acetate and hexane as an eluent by column chromatography, and the compound purity was found to be more than 99% with a satisfactory yield (69% to 83%). Synthesis, purification, and characterisation details of compounds **1a–1f**, **2a–2f**, and **3a–3d** were reported earlier from our research group⁴². The chemical structures of the newly synthesised compounds (**4a–4c**) have been ascertained with the help of spectroscopic techniques such as FT-IR, NMR (¹H and ¹³C), LC-MS, and elemental analysis. In LC-MS, the molecular ion peaks of these novel compounds (**4a–4c**) were in good agreement with their proposed molecular masses. Elemental analysis results of the title compounds (**4a–4c**) were within ±0.4% of the calculated values.

The primary goal of the current study was to investigate the impact of the substitution pattern, in terms of nature and position of substituents, at positions 1, 2, and 3 of the indolizine ring system on the anti-tubercular activity of the resultant analogues. The synthetic strategy for the development of the target compounds involved a 1,3-dipolar [3 + 2] cycloaddition as a key step, allowing the introduction of the substituent in the diverse position of the indolizine ring. The 1,3-dipolar [3 + 2] cycloaddition of pyridinium ylides with electron-deficient alkynes offered a convenient approach for the construction of an indolizine scaffold.

3.2. Crystallography

Compound **4b** was crystallised in the triclinic centrosymmetric space group *P*-1 with one molecule in the asymmetric unit. The parameters for crystal data collection and structure refinement, and the list of intramolecular and intermolecular interactions in the crystal structure of diethyl 3-(4-chlorobenzoyl)indolizine-1,2-



| Compound No. | R ₁ | Compound No. | R ₁ | R ₂ |
|--------------|------------------|--------------|------------------|--|
| 1a | -F | 2a | -F | H |
| 1b | -Cl | 2b | -Cl | H |
| 1c | -Br | 2c | -Br | H |
| 1d | -NO ₂ | 2d | -NO ₂ | H |
| 1e | -CH ₃ | 2e | -CH ₃ | H |
| 1f | -CN | 2f | -CN | H |
| | | 3a | -F | -CH ₃ |
| | | 3b | -Cl | -CH ₃ |
| | | 3c | -Br | -CH ₃ |
| | | 3d | -NO ₂ | -CH ₃ |
| | | 4a | -F | -CO ₂ CH ₂ CH ₃ |
| | | 4b | -Cl | -CO ₂ CH ₂ CH ₃ |
| | | 4c | -NO ₂ | -CO ₂ CH ₂ CH ₃ |

Scheme 1. Synthesis of 1,2,3-trisubstituted indolizine derivatives (**2a–2f**, **3a–3d**, **4a–4c**): Reagents and conditions (i) pyridine, dry acetone, stir at room temperature, 5 h; (ii) ethyl propionate/ethyl 2-butyrate/diethyl 2-butyndioate water, stir 80 °C, 3 h

dicarboxylate (**4b**) are given in Table S1 and Table 1, respectively. The side chain ethoxy groups do not exhibit any orientational disorder. The molecular conformation is locked via C-H...O H-bonds (involving H1/O5 and H4/O2) forming pseudo-six membered rings (Figure 3). The crystal packing is stabilised via C-H...O H-bonds (involving H21 and O5), forming dimers, and these are connected with centro symmetrically related dimers formed via C-H...O H-bonds (involving H17/H18 with O3) via additional C-H...O H-bonds (involving H3 and O3), thus leading to the overall formation of a "hexamer" in the solid-state (Figure 4). Thus, O3 functions as a "trifurcated acceptor" which is a unique feature in the packing of this molecule in the crystal. In addition, the molecules are connected via a π ... π stacking motif, involving the 6-membered ring (Cg1: centre of gravity of ring N1/C1-C5), the stacking distance being 3.654 Å. Finally, a short contact between O1 = C7...C5-N1 of distance 3.359 Å, involving electrophilic C7 and relatively less electrophilic C5 is present in the crystalline lattice (Figure 4).

3.3. Hirshfeld surface analysis and energy framework calculation

The Hirshfeld surfaces of the title compound **4b** were mapped over d_e , d_{norm} , shape index, curvedness, and fragment patches as

shown in Figure 5. The contribution of individual intermolecular interactions on the Hirshfeld surface can be identified through the colour codes. If d_i is greater than d_e , it is shown by the dark surface area that exists because of the acceptor of the hydrogen bond. The red colour spot indicates shorter molecular contacts on the d_{norm} surface, and the blue colour on the surface of the d_{norm} reflects longer molecular contacts. The white colour on the d_{norm} surface indicates the interaction around the van der Waals radii. The red colour spot indicates the hydrogen bonding H...O contacts in the d_{norm} surfaces, while the blue surface region represents the H...H contacts (Figure 5(a)). The characteristics of the d_e surface appear as a relatively flat green region where the distances of contact are similar (Figure 5(b)). The strong hydrogen bonding interactions present in the molecule (Figure 5(c)) are also demonstrated by the adjacent highlighted red and yellow regions on the shape index surface. Whereas, the H...H interactions (Figure 5(d)) are shown by the blue curved and yellow regions on the curvedness surfaces. The colour patches are mapped differently on the Hirshfeld surface depending on the closeness to the neighbouring molecules (Figure 5(e)). The 2D fingerprint plots indicate the sharp spike peak that reflects the strong hydrogen bonding present in the molecule (Figure 6(a-h)). The fingerprint plot shows that the H...H contacts have a comparatively larger contribution of 40.0% relative to other interactions and implies

Table 1. List of intramolecular and intermolecular interactions in the crystal structure of diethyl 3-(4-chlorobenzoyl)indolizine-1,2-dicarboxylate (**4b**).

| Interaction Type | D-H (Å) | D...A (Å) | H...A (Å) | D-H...A (°) | Symmetry code |
|------------------|---------|-----------|-----------|-------------|--------------------|
| C1-H1...O5 | 0.95 | 2.859 | 2.29 | 118 | x, y, z |
| C4-H4...O2 | 0.95 | 2.869 | 2.33 | 115 | x, y, z |
| C3-H3...O3 | 0.95 | 3.368 | 2.64 | 133 | $x, +y-1, +z$ |
| C18-H18...O3 | 0.95 | 3.175 | 2.58 | 121 | $-x+1, -y+2, -z$ |
| C17-H17...O3 | 0.95 | 3.188 | 2.60 | 120 | $-x+1, -y+2, -z$ |
| C21-H21...O5 | 0.95 | 3.369 | 2.47 | 159 | $-x+1, -y+1, -z+1$ |




Figure 3. The crystal structure of diethyl 3-(4-chlorobenzoyl)indolizine-1,2-dicarboxylate (**4b**). ORTEP drawn with 50% ellipsoidal probability. Intra-molecular C-H...O-H bonds are shown as dotted lines.




Figure 4. Crystal packing depicting C–H...O–H-bonds, π – π stacking interaction and O1=C7...C5–N1 short contact in the compound **4b**. Cg1 is the centre of gravity of N1/C1–C5 ring. The dotted lines represent intermolecular interactions. Non-interacting hydrogens have been omitted for clarity.




Figure 5. Hirshfeld surfaces mapped with (a) d_{norm} (b) d_e (c) shape-index, (d) curvedness and (e) fragment patches for the compound **4b**.

that van der Waals radii and hydrogen bonding play a key role in the crystal packing. The H...O contacts contribute 21.7% of the total interactions. In addition, the percentage contribution in this crystal structure of other intermolecular interactions are as follows: C...H/H...C (14.8%), H...Cl/Cl...H (13.1%), C...C (3.5%), C...O/O...C (3.2%), N...C/C...N (1.3%), O...Cl/Cl...O (1.1%), N...H/H...N (0.7%), O...N/N...O (0.4%), Cl...C/C...Cl (0.1%).

Systematic and theoretical energy was measured in terms of electrostatic, dispersion, and total energy using the program Crystal Explorer software, which further facilitated to depict the 3D topological images for the compound **4b** (detailed information is provided in the supplementary section [Figures S10–S13](#) and [Table S2](#)).

3.4. Anti-tubercular activity

The anti-tubercular activity of the target compounds (**2a–2f**, **3a–3d**, and **4a–4c**) was evaluated (*in vitro*) against two different MTB strains, namely susceptible H37Rv MTB strain, and rifampicin and isoniazid-resistant MTB strain ([Table 2](#)). Rifampicin and

isoniazid were also used as positive controls ([Table 2](#)). The anti-mycobacterial activity showed that compound **3a**, substituted with a fluorine atom at the 4-position of the benzoyl group and a methyl group at the 2-position of the indolizine ring, is the most potent molecule demonstrating the highest inhibitory action against the susceptible H37Rv MTB strain with MIC value of 4 $\mu\text{g/mL}$. Five Compounds (**2b**, **2d**, **3d**, **4a**, and **4b**) were found to be equipotent, with a MIC value of 8 $\mu\text{g/mL}$. Compounds **2c**, **3b**, and **4c** showed moderate anti-TB activity with a MIC value of 32 $\mu\text{g/mL}$ against the same strain. Meanwhile, no activity was observed for the remaining indolizines against the H37Rv MTB strain.

The structure–activity relationship (SAR) analysis revealed the presence of a hydrogen atom, a methyl or an ester substituent at the 2-position of the indolizine core was favourable to attain good anti-tubercular activity. The presence of the halogen and the nitro group at the *para* position of the benzoyl ring were found to be tolerated well to maintain the activity (except compounds **2a** and **3c**) against the H37Rv MTB strain, whilst the substitution with methyl and cyano group in compounds **2e** and **2f**, respectively, completely abolished the activity against both the




Figure 6. Two-dimensional fingerprint plot for the compound **4b** showing the contributions of individual types of interactions: (a) all intermolecular contacts, (b) H...H contacts, (c) O...H/H...O contacts, (d) C...H/H...C contacts, (e) Cl...H/H...Cl contacts, (f) C...C contacts, (g) C...O/O...C contacts, (h) N...C/C...N. The outline of the full fingerprint is indicating in grey. The related surface patches associated with the specific contacts with the d_{nom} mapped are illustrated by surfaces to the left.

MTB strains. In the case of nitro derivatives, compounds **2d** and **3d** with a hydrogen and methyl group, respectively, at the 2-position of the indolizine ring showed four-fold increased activity as compared with the compound **4c** with an ester group at the same position.


The structural alteration at the 2-position of the indolizine scaffold resulted in a profound impact on the anti-mycobacterial activity against MDR-MTB. The indolizine derivatives that were active (**2b–2d**, **3a**, **3b**, and **3d**) against the susceptible **H37Rv** MTB strain were found to be inactive against MDR-MTB, except for compounds **2d** and **3a** which exhibited 8-fold reduced MDR-MTB activity compared to **H37Rv** MTB strain (Table 2). However, compounds **4a–4c** with an ethyl ester group at the 4-position of the benzoyl ring showed moderate activity against MDR-TB, with a two-fold decrease in potency as compared with the cellular activity against susceptible **H37Rv** MTB strain. The anti-tubercular activity profile of the tested compounds against MDR-MTB provided a clue for their mode of action. Indeed, the results demonstrated that the first and second series of indolizines (**2a–2f** and

3b–3d) did not show activity against MDR-MTB except for compounds **2d** and **3a**, while the third series of compounds **4a–4c** clearly inhibited the MDR-MTB strain. These findings suggest that the three designed series are likely to be inhibiting different MTB molecular drug targets; such that the first and second series of indolizine derivatives are inhibiting a common target that is different from that inhibited by the third series. Alternatively, the compounds that retained activity against MDR-MTB strain (third series) could be interacting with the same molecular target as those of the first two series, yet, might be interacting differently with the target binding site.

The above findings and observations supported the view that the first and second series of indolizine were more likely to inhibit the mycobacterial cell growth by interacting with the InhA enzyme. With regards to the mode of action of the ester indolizine series 3, their differences in inhibitory activity between susceptible strains and clinical isolates of MDR-MTB strains suggested that the derivatives **4a–4c** were interacting with another molecular target. Thus, further molecular modelling study was carried out

to elucidate the potential mode of action of the tested compounds as well as to rationalise their SAR as inhibitors of InhA which represents one of the potential MTB therapeutic targets,

Table 2. *In vitro* anti-mycobacterial activity of 1,2,3-trisubstituted indolizine derivatives (**2a–2f**, **3a–3d**, and **4a–4c**) against H37Rv and MDR strains of *Mycobacterium tuberculosis*.



| Entry | R ₁ | R ₂ | MIC (μg/mL) | |
|------------|---|-----------------|--------------------|----------------------|
| | | | H37Rv ^a | MDR-MTB ^b |
| 2a | H | F | NA | NA |
| 2b | H | Cl | 8 | NA |
| 2c | H | Br | 32 | NA |
| 2d | H | NO ₂ | 8 | 64 |
| 2e | H | CH ₃ | NA | NA |
| 2f | H | CN | NA | NA |
| 3a | CH ₃ | F | 4 | 32 |
| 3b | CH ₃ | Cl | 32 | NA |
| 3c | CH ₃ | Br | NA | NA |
| 3d | CH ₃ | NO ₂ | 8 | NA |
| 4a | CO ₂ CH ₂ CH ₃ | F | 8 | 16 |
| 4b | CO ₂ CH ₂ CH ₃ | Cl | 8 | 16 |
| 4c | CO ₂ CH ₂ CH ₃ | NO ₂ | 32 | 64 |
| Rifampicin | | | <1 | ≥1 |
| Isoniazid | | | <0.2 | ≥0.2 |

^aAmerican Type Culture Collection (ATCC): 25177; ^bthese isolates were found to be resistant to the first line antibiotics, rifampicin (1 μg/mL), and isoniazid (0.2 μg/mL). MDR-MTB: multidrug-resistant strains of *Mycobacterium tuberculosis*; MIC: minimum inhibitory concentration; NA: not active at the concentration range (0.2–64 μg/mL).

and also to identify the second molecular target for the ester indolizine series 3.

3.5. Toxicity study

The promising activities of the designed compounds are very encouraging to undertake prospective optimisation cycles. However, it is highly recommended to optimise the ADMET properties for a lead compound early in the development stage to reduce later problems due to unfavourable ADMET characteristics^{53,54}. Based on the *in silico* calculated ADME and toxicity parameters (Table 3), all the compounds are showing acceptable ADMET profile which makes them worthy of further optimisation towards achieving the desired drug-like properties.

Moreover, the toxicity profile for compounds **2d**, **3a**, **4a**, **4b**, and **4c** that showed promising activity against MDR-MTB was further assessed against peripheral blood mononuclear cells (PBMCs) and no signs of toxicity were observed with concentrations up to 256 μg/mL.

3.6. Computational molecular modelling

A molecular docking study was carried out to gain insight into the mechanism of action of the indolizine derivatives (**2a–2f**, **3a–3d**, and **4a–4c**). In light of the MTB inhibitory action, InhA appeared to be a potential molecular target for the title compounds; therefore these compounds were docked against InhA enzyme in an attempt to corroborate their mode of action with their observed anti-mycobacterial activity.

The binding feature common to all InhA inhibitors is the active participation of NAD, as a cofactor, contributing strong interaction with substrates through the H-bonding involvement from its

Table 3. Calculated ADMET descriptors and toxicity parameters of indolizine derivatives (**2a–2f**, **3a–3d**, and **4a–4c**).

| Compounds | | MIC (µg/mL) | | ADMET descriptors ^a | | | | | | | | Toxicity parameters ^b | | | | | | | | | |
|-----------|------|-------------|------|--------------------------------|----|-------|-------------------|----------------|------|-------|---------|----------------------------------|-------|-------|-------|-------|-------|-----|-------|-------|-----|
| Index | Code | H37Rv | MDR- | | AS | BBB | CYP2D6 inhibition | Hepatotoxicity | HIA | PPB | AlogP | PSA | AM | SI | OI | AB | DTP | CMR | CFR | CLM | CFM |
| | | | MTB | | | | | | | | | | | | | | | | | | |
| 1 | 2a | NA | NA | 2 | 1 | True | True | 0 | True | 3.767 | 48.88 | 0 | 0.156 | 0.051 | 0 | 0 | 0.001 | 0 | 0.248 | 1 | |
| 2 | 2b | 8 | NA | 2 | 1 | True | False | 0 | True | 4.226 | 48.88 | 0 | 0.002 | 0.05 | 0 | 0 | 0.001 | 0 | 0 | 1 | |
| 3 | 2c | 32 | NA | 2 | 1 | False | False | 0 | True | 4.31 | 48.88 | 0 | 0 | 0.05 | 0.012 | 0 | 0.001 | 0 | 0 | 0.999 | |
| 4 | 2d | 8 | 64 | 2 | 3 | False | True | 0 | True | 3.456 | 91.703 | 0.062 | 0 | 0.84 | 0.001 | 0 | 0.008 | 0 | 0.976 | 1 | |
| 5 | 2e | NA | NA | 2 | 1 | False | False | 0 | True | 4.048 | 48.88 | 0 | 0 | 0.036 | 0 | 0 | 0 | 0 | 0 | 1 | |
| 6 | 2f | NA | NA | 2 | 2 | False | False | 0 | True | 3.441 | 71.815 | 0.945 | 0 | 0.359 | 0 | 0 | 0 | 0 | 0 | 1 | |
| 7 | 3a | 4 | 32 | 2 | 1 | True | True | 0 | True | 4.254 | 48.88 | 0 | 0.731 | 0.447 | 0 | 0.976 | 0.001 | 0 | 0.001 | 1 | |
| 8 | 3b | 32 | NA | 2 | 1 | False | False | 0 | True | 4.712 | 48.88 | 0 | 0.028 | 0.468 | 0 | 0.99 | 0.001 | 0 | 0 | 0.989 | |
| 9 | 3c | NA | NA | 2 | 1 | False | False | 0 | True | 4.796 | 48.88 | 0 | 0.006 | 0.476 | 0.985 | 0.992 | 0.001 | 0 | 0 | 0.861 | |
| 10 | 3d | 8 | NA | 2 | 2 | False | True | 0 | True | 3.942 | 91.703 | 0.012 | 0 | 0.984 | 0.129 | 0.956 | 0.008 | 0 | 0.188 | 0.996 | |
| 11 | 4a | 8 | 16 | 2 | 2 | False | True | 0 | True | 3.972 | 75.11 | 0 | 0.993 | 0.034 | 0.487 | 0.117 | 0.008 | 0 | 0 | 1 | |
| 12 | 4b | 8 | 16 | 2 | 1 | False | False | 0 | True | 4.43 | 75.11 | 0 | 0.478 | 0.04 | 0.521 | 0.239 | 0.008 | 0 | 0 | 0.599 | |
| 13 | 4c | 32 | 64 | 2 | 4 | True | True | 1 | True | 3.661 | 117.933 | 0.069 | 0.004 | 0.642 | 1 | 0.068 | 0.117 | 0 | 0.001 | 0.806 | |

Aqueous solubility (AS)

| Level | Value | Drug-likeness | Level | Value | Description | Level | Description |
|-------|-----------------------|----------------------------|-------|-----------|---|-------|---------------------|
| 0 | log(Sw) < −8.0 | Extremely low | 0 | Very High | Brain-Blood ratio greater than 5:1 | 0 | Good absorption |
| 1 | −8.0 < log(Sw) < −6.0 | No, very low, but possible | 1 | High | Brain-Blood ratio between 1:1 and 5:1 | 1 | Moderate absorption |
| 2 | −6.0 < log(Sw) < −4.1 | Yes, low | 2 | Medium | Brain-Blood ratio between 0.3:1 and 1:1 | 2 | Low absorption |
| 3 | −4.1 < log(Sw) < −2.0 | Yes, good | 3 | Low | Brain-Blood ratio less than 0.3:1 | 3 | Very low absorption |
| 4 | −2.0 < log(Sw) ≤ 0.0 | Yes, optimal | 4 | Undefined | Outside 99% confidence ellipse | | |
| 5 | 0.0 < log(Sw) | No, too soluble | | | | | |

| Probability values | Probability level | Description |
|--------------------------------------|--------------------------|---|
| 0.0–0.30 | Low probability | Such a chemical is not likely to produce a positive response in an experimental assay |
| Greater than 0.30 but less than 0.70 | Intermediate probability | |
| Greater than 0.70 | High probability | Likely to produce a positive response in an experimental assay |

^aKey to the above calculated ADMET descriptors.

^bKey to the above calculated toxicity parameters.

ribose hydroxyl moiety. Additionally, the residue LYS 165 participates in the binding network by interacting with the hydroxyl oxygen of the NAD ribose through hydrogen bonding, and the residue ILE 91 is engaged in H-bonding with the amide functionality of the nicotinamide part of NAD. These residues greatly contributed to the stability of the cofactor. Hence, the latter tends to play a critical role in molecular interaction with the substrate and other residues in the InhA binding domain. Consequently, the presence of NAD during a docking study may have a profound effect not only on the ligand interaction but also on the occupancy size of the active site that may affect ligand orientation. Besides, a great majority of reported InhA inhibitors make a stable hydrogen bonding to the backbone hydroxyl group of the main chain TYR 158, responsible for blocking the enoyl-acyl carrier protein reductase function⁵⁵. The role of TYR 158 in the catalytic mechanism of InhA has been the focus of many studies which revealed that its side chain can adopt different conformations when direct InhA inhibitors bind the catalytic site. Mainly two conformations were identified, an “in” and “out” conformations. The former is resembling the substrate-NAD-InhA ternary complex, and the latter resembles the NAD-InhA binary complex (Figure 7); however, in the majority of available InhA-inhibitor complexes TYR158 is in the “in” conformation and the inhibitor is forming interactions with the cofactor^{56–58}. However, a novel binding mode of a benzimidazole-based InhA inhibitor has been recently disclosed, occupying an extended hydrophobic pocket formed by the amino acid residues Phe149, Met155, Pro156, Ala157, and Ile215 in the in-Tyr 128 conformation⁵⁷. Certain InhA inhibitors were also reported to co-crystallize with Tyr 158-out active site residue^{59–65}.

Accordingly, the binding mode of the indolizine **2d** was investigated by docking it into the active site of the InhA enzyme utilising crystal structures of the in and out conformations, namely 5G0S and 5G0U respectively (Figure 8).

The docking results revealed that the estimated binding energy of **2d** was -107.46 kcal/mol and -144.02 kcal/mol with the InhA binding site 5G0U (Tyr 158-out) and 5G0S (Tyr 158-in) respectively, indicating that the indolizine **2d** interacted more favourably with the in Tyr 158 conformation active residue. Indeed, the binding

pose of **2d** showed three hydrogen bond contacts with active site's residues in the “in” conformation (pdb 5G0S), while only one with the “out” conformation (pdb 5G0U) (Figure 8). The binding mode of **2d** revealed that the benzoyl ring occupies the same location in both the crystal involving H-bond interaction with the co-factor NAD but differ on the orientation of the indolizine ring (Figure 8). In light of the comparative docking analysis the InhA crystal structure of 5G0S, “in” conformation, appeared as more appropriate to investigate the binding patterns. Hence, docking of the remaining derivatives was performed with the Tyr 158-in conformation InhA active site (PDB 5G0S). The docking results, reported in Table 4, indicated that the active indolizines **2b–2d**, **3a**, **3b**, and **4a–4c** displayed greater binding energy as compared to that of inactive congeners **2a**, **2e**, **2f**, and **3c**. In general, the predicted docking energy of indolizines was consistent with the observed MTB inhibitory activity of the tested compounds, except for the compounds **2d**, **3d**, and **4c** with a nitro substitution (Figure 9). However, the order of the potency in the second indolizine series was **3a** (F) > **3b** (Cl) >> **3c** (Br) which correlates with the docking scores. A similar correlation between the activity and docking scores was also observed in the first indolizine series in which the order of bioactivity was **2b** (Cl) > **2c** (Br) >> **2a** (F), **2f** (CN), **2e** (CH₃). Among the compounds **2a** and **3a**, the most active compound **3a** (F) displayed a higher binding energy score than the inactive compound **2a** (F). The compound **2b** (Cl) being more active than compound **3b** (Cl) demonstrated a higher energy score. A similar trend was also observed for the bromine derivatives **2c** and **3c**. The nitro compounds **2d** and **3d** were equipotent and showed comparable docking scores. As for the third series, the indolizines **4a–4c** showed very high docking scores. The equipotent indolizines **4a** (F) and **4b** (Cl) showed comparable docking scores, whilst the nitro derivative **4c** showing a higher docking score was four-fold less potent than the compounds **4a** and **4b**.

The observed MTB inhibitory activity pattern of the indolizines can be accounted for their distinctive feature of binding mode into the InhA active site. The key binding interaction of the title compounds was highlighted in Figures 9 and 10. The binding poses of the title compounds showed that the benzoyl ring is




Figure 7. The two reported “in and out” conformations of Tyr158 in mycobacterial InhA enzyme. PDB ID for the in conformation is 5G0S, and that for the out conformation is 5G0U.




Figure 8. Comparative binding mode of indolizine **2d** into InhA binding domain with (a) in-Tyr 158 (PDB ID: 5G0S) and (b) out-Tyr 158 conformations (PDB ID: 5G0U), respectively. The ligand, NAD and the receptor were represented as sticks in salmon, yellow and cyan colours respectively. The hydrogen bonds are shown as green dotted lines.

Table 4. Docking results of the indolizine derivatives **2a–2f**, **3a–3d** and **4a–4c** into the InhA binding domain (PDB 5G0S).

| Entry | R ₁ | R ₂ | Binding E. (Kcal/mol) | Residues Interaction | |
|---------------|---|-----------------|--------------------------|----------------------------------|-------------------|
| | | | | H-Bond (Dist. Å, atom) | Pi-interaction |
| 2a | H | F | −114.75 | Tyr 158 (2.71, F) | |
| 2b | H | Cl | −128.17 | Met 98 (2.32, CO benzoyl) | Phe 97 (Pi–Pi) |
| 2c | H | Br | −120.18 | Met 98 (2.37, CO benzoyl) | Phe 97 (Pi–Pi) |
| 2d | H | NO ₂ | −144.02 | Met 98 (2.13, CO benzoyl) | Phe 97 (Pi–Pi) |
| | | | | Tyr 158 (2.56, NO ₂) | Met 103 (Pi–S) |
| | | | | NAD (2.00, NO ₂) | |
| 2e | H | CH ₃ | −97.47 | | |
| 2f | H | CN | −99.48 | | |
| 3a | CH ₃ | F | −152.37 | Met 98 (2.27, CO benzoyl) | Phe 97 (Pi–Pi) |
| | | | | NAD (2.19, F) | Met 103 (Pi–S) |
| 3b | CH ₃ | Cl | −124.20 | Met 98 (2.15, CO benzoyl) | Phe 97 (Pi–Pi) |
| | | | | | Met 103 (Pi–S) |
| 3c | CH ₃ | Br | −104.21 | | |
| 3d | CH ₃ | NO ₂ | −147.40 | Met 98 (2.13, CO benzoyl) | Phe 97 (Pi–Pi) |
| | | | | Tyr 158 (2.55, NO ₂) | Met 103 (Pi–S) |
| | | | | NAD (1.99, NO ₂) | |
| 4a | CO ₂ CH ₂ CH ₃ | F | −165.58 | Met 98 (2.32, CO benzoyl) | Phe 97 (Pi–Pi) |
| | | | | Tyr 158 (3.53, F) | Met 103 (Pi–S) |
| | | | | NAD (2.82, F) | |
| 4b | CO ₂ CH ₂ CH ₃ | Cl | −165.95 | Met 98 (2.45, CO benzoyl) | Phe 97 (Pi–Pi) |
| | | | | | Met 103 (Pi–S) |
| 4c | CO ₂ CH ₂ CH ₃ | NO ₂ | −182.03 | Met 98 (2.04, CO benzoyl) | |
| | | | | Tyr 158 (2.93, NO ₂) | |
| | | | | NAD (2.01, NO ₂) | |
| Native ligand | | | −186.54 | Met 98 (1.97) | Phe 149 (Pi – Pi) |
| | | | | Gln 100 (2.41) | |
| | | | | Tyr 158 (2.82) | |
| | | | | NAD (2.06) | |

located near to the co-factor binding site with a sandwich orientation between the nicotinamide ring of NAD and the main chain Tyr 158 which is consistent with the binding mode of known InhA inhibitors. The active indolizines **2b–2d**, **3a**, **3b**, and **4a–4c** were predicted to adopt a similar conformation in the binding domain by forming strong hydrogen bonding with the residue Met 98 and the carbonyl moiety of the benzoyl group, whereas the carbonyl moiety of the benzoyl group for the inactive indolizines **2a**, **2e**, **2f**, and **3c** was orientated away from the residue Met 98 preventing the H-bonding interaction (Figure 9). The conformation

alteration from the rotation of the benzoyl group could provide a rationale for the lack of potency observed for these derivatives. However, the interaction of the residue Met 98 with the native ligand and certain InhA inhibitors is reported as well^{61,62}. It was also demonstrated that interacting with the Met 98 residue through H-bonding was the key interaction to retain the MTB inhibitory activity when the main chain Tyr 158 was not involved in any hydrogen bonding with the ligand.⁵⁹ Derivatives **2d**, **3a**, **3d**, **4a**, and **4c** were able to make additional hydrogen bonding contacts with residues in the active site. For instance, the *para* nitrobenzoyl




Figure 9. Predicted binding interaction of indolizines (**2a**, **2b**, **2d**, **3a**, **3b**, **3d**, **4a–4c**) with InhA binding domain (PDB 5G0S). Ligand and receptor were represented as salmon and cyan respectively. Hydrogen bonding contact is shown with green dotted lines. π - π , π -sulfur and hydrophobic interactions are shown with magenta, gold and violet, respectively. For displaying key binding interaction, NAD has been omitted.

indolizines **2d**, **3d**, and **4c** showed two H-bonding interactions between the nitro group and the residue Tyr 158 and the hydrogen atom of the hydroxyl group from the NAD ribose (Figure 10). Similarly, the derivative **4a** having a fluorine atom in the para position of the benzoyl moiety showed a moderate hydrogen bonding contact with the hydroxyl group of the NAD ribose and a weak H-bond with the residue Tyr 158, while compound **3a** demonstrated only one strong H-bond with the hydroxyl of the NAD ribose but exempting from any H-bond interaction with the residue Tyr 158 (Figure 10). The strength of H-bonding involvement with NAD ribose may explain the greater potency observed for the derivative **3a** (2.19 Å) as compared to the compound **4a** (2.82 Å).

Another important contribution to the cellular activity of the bioactive compounds is the hydrophobic interaction implicated by the residues Phe 97 and Met 103 (Figure 9 and Table 4), Where Phe 97 formed T-shaped pi-stacking interaction with the indolizine ring, except for compound **4c**, and the residue Met 103 was observed to interact with the indolizine ring through pi-sulfur interactions with the exception of compounds **2b** and **4c**. The

lack of hydrophobic interaction with the residues Phe 97 and Met 103 for the compound **4c** (NO_2) provides an explanation for its reduced potency in comparison with its nitro congeners **2d** and **3d** (Figure 9).

The molecular modelling analysis indicated that the observed MTB potency of indolizines was in good agreement with the predicted binding mode and binding energy predictions. These computational results strongly support our assumption that the molecular target of the designed indolizine is enoyl-acyl carrier protein reductase, and the key interactions with the residues Met 98 and Phe 91 were highlighted as being mainly responsible for the observed activity of the compounds. These findings could provide a valuable guide to designing more potent indolizines as potential InhA inhibitors through a structure-based design approach.

We next focussed on the prospective identification of the cellular target of the ester derivatives **4a–4c**. According to the cellular activity profile against MDR MTB, the ester indolizine series **4a–4c**, identified as potential InhA inhibitors, may have more than one molecular MTB target. In the quest to identify the second






Figure 10. Predicted binding interaction of indolizines (**4a**, **4c**) with InhA binding domain (PDB 5G0S). Ligand, NAD and receptor were represented as salmon, yellow and cyan respectively. Hydrogen bonding contact is shown with green dotted lines.

Table 5. Docking results of the indolizine derivatives **4a–4c** into the anthranilate phosphoribosyl binding domain (PDB 3R6C).


| Entry | R ₁ | R ₂ | Binding E. (Kcal/mol) | Residues Interaction | |
|-----------|--------------------|-----------------|--------------------------|--|---|
| | | | | H-Bond (Dist. Å, atom) | Hydrophobic |
| 4a | CO ₂ Et | F | −170.37 | Arg 193 (2.09, CO benzoyl) Ans 138 (2.41, CO ester) | Gly 107 (3.58, F) Thr 108 (3.51, F) Arg 193 (3.40, Pi-cation) |
| 4b | CO ₂ Et | Cl | −166.81 | Arg 193 (2.16, CO benzoyl) Ans 138 (2.24, CO ester) | Gly 107 (3.22, Cl) Arg 193 (3.31, Pi-cation) |
| 4c | CO ₂ Et | NO ₂ | −140.06 | Ans 138 (2.15, CO ester) | |



Indolizine 4a



Indolizine 4b



Indolizine 4c

Figure 11. Predicted binding interaction of indolizines (**4a–4d**) with anthranilate phosphoribosyl binding domain (PDB 3R6C). Ligand and receptor were represented as salmon and cyan respectively. Hydrogen bonding contact is shown with green dotted lines. Halogen bonding and hydrophobic interactions are shown with cyan and violet respectively.

potential target for the indolizines **4a–4c**, again, computational molecular docking studies were carried out. Based on the MTB activity of derivatives **4a–4c** against both susceptible and resistant MTB strains, we hypothesised that the presence of the ester functional group at 2-position of the indolizine may strongly contribute to the bioactivity through the formation of hydrogen bonding contact. Furthermore, it has been observed that the indolizine **4a** and **4b**, having halogen substituent in the para position of the benzoyl moiety, had exhibited identical anti-TB activity and were more active than the nitro derivative **4c**, indicative of probable

involvement of halogen bonding interaction with the receptor. With regards to the above considerations, a large number of known TB molecular targets were screened. The molecular target anthranilate phosphoribosyltransferase appeared to be the appropriate enzyme target for indolizines **4a–4c**. The docking scores, presented in Table 5, were also found to be consistent with the MTB activity of the compounds in which the equipotent indolizines **4a** and **4b** displayed similar binding energy, while the less active indolizine **4c** showed a lower docking score. The binding interaction of the indolizines **4a–4c** with the anthranilate

phosphoribosyl enzyme was illustrated in Figure 11. The most active compounds **4a** and **4b** were found to adopt similar orientation in the anthranilate phosphoribosyl binding domain showing two strong hydrogen bonding contacts between the carbonyl group of benzoyl and ester at 2-position of indolizine ring with the amino acid residues Arg 193 and Asn 138, respectively. Among the numerous hydrophobic interactions, the fluorine atom of compound **4a** showed halogen interaction with the residues Gly 107 and Thr 108, similarly, the chlorine atom of compound **4b** exhibited interaction with the residue Gly 107. Both indolizines **4a** and **4b** were also involved in pi-cation interaction between the benzoyl ring of the indolizine and the residue Arg 193. The binding mode of the indolizine **4c** differed from its congeners demonstrating only one H-bond contact between the residue Asn 138 and the carbonyl of ester group at the 2-position of indolizine ring, explaining the lower observed MTB activity. However, although the above computational results reasonably explained the observed anti-tubercular activities of the tested compounds, yet, they need to be experimentally verified and validated via bio-molecular *in vitro* testing. Thus, it could be the subject of prospective research due to its importance in confirming the *in silico* results that is imperative to guide prospective optimisation of these lead compounds towards designing more potent and selective drug candidates.

4. Conclusion

In the current study, three novel series of 1,2,3-trisubstituted indolizine derivatives (**2a–2f**, **3a–3d**, and **4a–4c**) were evaluated for their anti-TB activity against susceptible and MDR-MTB strains. The majority of tested compounds showed good to excellent anti-tubercular activity with MIC ranging from 4 to 64 µg/mL. The inhibition profile of indolizines and molecular docking strongly supported that InhA is the principal drug target for the investigated compounds. Molecular modelling insight indicated that the conformation changes resulting from the benzoyl group rotation provided a rationale for the MTB cellular activity of the indolizines as InhA inhibitor. Furthermore, the cellular activity profile of the ester indolizine derivatives (**4a–4c**) against both the strains revealed their inhibitory action in multiple molecular targets in which anthranilate phosphoribosyltransferase might be a potential additional drug target. Our results highlighted the importance of indolizines as a novel promising class of multi-targeting agents for MTB with favourable toxicity profile. Such compounds might serve as attractive leads for further development of potential drug candidates for combating both the drug-sensitive and drug-resistant tuberculosis strains.

The compound **4b** was crystallised in a triclinic centrosymmetric crystal system with space group *P*-1. In stabilising the molecular structure, the C–H...O and other short contact have played an important role. Hirschfeld surface analysis with 2D fingerprint plots was performed to provide insight into the stability of the crystal structure in order to understand and visualise the contribution of distinct intermolecular interactions. Systematic and theoretical energy was measured in terms of electrostatic, dispersion, and total energy using the program *Crystal Explorer* software, which further depicts 3D topological images.

Funding

This research was funded by the Deputyship for Research & Innovation, Ministry of Education in Saudi Arabia (Research Project Number 1058).

Acknowledgements

The authors extend their appreciation to the Deputyship for Research & Innovation, Ministry of Education in Saudi Arabia for funding this research work through the project number 1058, King Faisal University, Kingdom of Saudi Arabia for support and encouragement; the Department of Microbiology, National Health Laboratory Services, Inkosi Albert Luthuli Central Hospital, Durban South Africa for providing the facility to carry out *in vitro* anti-TB activity and Dr. Hong Su, Center for Supramolecular Chemistry Research, Department of Chemistry, University of Cape Town, South Africa, for single-crystal X-ray data collection. D.C. thanks IISER Bhopal for research facilities and infrastructure. R.D.N and S.K.N. thank the Department of Chemistry, VNIT, Nagpur for support and encouragement. The authors wish to thank Mr. Tameem M. Alyahian for providing technical support in this project.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

This research was funded by the Deputyship for Research & Innovation, Ministry of Education of Saudi Arabia (Research Project Number 1058).

ORCID

Katharigatta N. Venugopala  <http://orcid.org/0000-0003-0680-1549>
 Pran Kishore Deb  <http://orcid.org/0000-0002-8650-2874>
 Nizar A. Al-Shar'i  <http://orcid.org/0000-0002-1599-5704>
 Lina A. Dahabiyeh  <http://orcid.org/0000-0002-4688-7052>
 Bandar E. Aldhubiab  <http://orcid.org/0000-0002-2684-4186>
 Anroop B. Nair  <http://orcid.org/0000-0003-2850-8669>
 Raghuprasad Mailavaram  <http://orcid.org/0000-0001-6126-5860>

References

1. World Health Organization. Global tuberculosis report. Available from: http://www.who.int/tb/publications/global_report/en/ [last accessed 9 June 2020].
2. World Health Organization. Global tuberculosis report 2019 (Executive summary). Available from: https://www.who.int/tb/publications/global_report/tb19_Exec_Sum_12Nov2019.pdf?ua=1 [last accessed 9 September 2020].
3. World Health Organization. TB/HIV facts. Available from: http://www.who.int/tb/challenges/hiv/factsheet_hivtb_2011pdf [last accessed 8 March 2016].
4. World Health Organization. Global tuberculosis report. Available from: <http://www.who.int> [Last accessed 1 May 2017].
5. Campbell PJ, Morlock GP, Sikes RD, et al. Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 2011;55:2032–41.
6. Velayati AA, Masjedi MR, Farnia P, et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super

- extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. *Chest* 2009;136:420–5.
7. Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. *Lancet* 2010;375:1798–807.
8. Singh P, Raj R, Kumar V, et al. 1,2,3-Triazole tethered beta-lactam-chalcone bifunctional hybrids: synthesis and anticancer evaluation. *Eur J Med Chem* 2012;47:594–600.
9. Baker MA, Lin HH, Chang HY, Murray MB. The risk of tuberculosis disease among persons with diabetes mellitus: a prospective cohort study. *Clin Infect Dis* 2012;54:818–25.
10. Patpi SR, Pulipati L, Yogeewari P, et al. Design, synthesis, and structure–activity correlations of novel dibenzo[b,d]-furan, dibenzo[b,d]thiophene, and N-methylcarbazole clubbed 1,2,3-triazoles as potent inhibitors of *Mycobacterium tuberculosis*. *J Med Chem* 2012;55:3911–22.
11. van Heeswijk RP, Dannemann B, Hoetelmans RM. Bedaquiline: a review of human pharmacokinetics and drug-drug interactions. *J Antimicrob Chemother* 2014;69:2310–8.
12. Nguyen TVA, Anthony R, Bañals A-L, et al. Bedaquiline resistance: its emergence, mechanism and prevention. *Clin Infect Dis* 2018;66:1625–30.
13. Fujiwara M, Kawasaki M, Hariguchi N, et al. Mechanisms of resistance to delamanid, a drug for *Mycobacterium tuberculosis*. *Tuberculosis* 2018;108:186–94.
14. Keam SJ. Pretomanid: first approval. *Drugs* 2019;79:1797–803.
15. Tetali SR, Kunapaeddi E, Mailavaram RP, et al. Current advances in the clinical development of anti-tubercular agents. *Tuberculosis* 2020;125:101989.
16. Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. *Am J Resp Crit Care Med* 2003;167:1472–7.
17. Grüber G. Introduction: novel insights into TB research and drug discovery. *Prog Biophys Mol Biol* 2020;152:2–5.
18. Stelitano G, Sammartino JC, Chiarelli LR. Multitargeting compounds: a promising strategy to overcome multi-drug resistant tuberculosis. *Molecules* 2020;25:1239.
19. Li W, Upadhyay A, Fontes FL, et al. Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 2014;58:6413–23.
20. Ganihigama DU, Sureram S, Sangher S, et al. Antimycobacterial activity of natural products and synthetic agents: pyrrolodiquinolines and vermelhotin as anti-tubercular leads against clinical multidrug resistant isolates of *Mycobacterium tuberculosis*. *Eur J Med Chem* 2015;89:1–12.
21. Khedr MA, Pillay M, Chandrashekarappa S, et al. Molecular modeling studies and anti-TB activity of trisubstituted indolizine analogues; molecular docking and dynamic inputs. *J Biomol Struct Dyn* 2018;36:2163–78.
22. Venugopala KN, Chandrashekarappa S, Pillay M, et al. Computational, crystallographic studies, cytotoxicity and anti-tubercular activity of substituted 7-methoxy-indolizine analogues. *PLoS One* 2019;14:e0217270.
23. Venugopala KN, Tratratt C, Pillay M, et al. Anti-tubercular activity of substituted 7-methyl and 7-formylindolizines and in silico study for prospective molecular target identification. *Antibiotics* 2019;8:247–16.
24. Dannhardt G, Meindl W, Gussmann S, et al. Anti-mycobacterial 7-hydroxy-2,3-dihydro-1H-indolizin-5-ones. *Eur J Med Chem* 1987;22:505–10.
25. Weide T, Arve L, Prinz H, et al. 3-Substituted indolizine-1-carbonitrile derivatives as phosphatase inhibitors. *Bioorg Med Chem Lett* 2006;16:59–63.
26. Olaru A-M, Vasilache V, Danac R, Mangalagiu II. Antimycobacterial activity of nitrogen heterocycles derivatives: 7-(pyridine-4-yl)-indolizine derivatives. Part VII8–12. *J Enzyme Inhib Med Chem* 2017;32:1291–8.
27. Gundersen L-L, Charnock C, Negussie AH, et al. Synthesis of indolizine derivatives with selective antibacterial activity against *Mycobacterium tuberculosis*. *Eur J Pharma Sci* 2007;30:26–35.
28. Dawood KM, Abbas AA. Inhibitory activities of indolizine derivatives: a patent review. *Expert Op Therap Patents* 2020;30:695–714.
29. Singh GS, Mmatli EE. Recent progress in synthesis and bio-activity studies of indolizines. *Eur J Med Chem* 2011;46:5237–57.
30. Sandeep C, Venugopala KN, Mohammed AK, et al. Review on chemistry of natural and synthetic indolizines with their chemical and pharmacological properties. *J Basic Clin Pharma* 2016;8:49–61.
31. Venugopala KN, Uppar V, Sandeep C, et al. Cytotoxicity and antimycobacterial properties of pyrrolo[1,2-a]quinoline derivatives: molecular target identification and molecular docking studies. *Antibiotics* 2020;9:233–14.
32. Venugopala KN, Tratratt C, Pillay M, et al. In silico design and synthesis of tetrahydropyrimidinones and tetrahydropyrimidinethiones as potential thymidylate kinase inhibitors exerting anti-TB activity against *Mycobacterium tuberculosis*. *Drug Design Dev Ther* 2020;14:1027–39.
33. Venugopala KN, Tratratt C, Chandrashekarappa S, et al. Anti-tubercular potency and computationally-assessed drug-likeness and toxicology of diversely substituted indolizines. *Ind J Pharma Educ Res* 2019;53:545–52.
34. Venugopala KN, Khedr MA, Pillay M, et al. Benzothiazole analogs as potential anti-TB agents: computational input and molecular dynamics. *J Biomol Struct Dyn* 2019;37:1830–42.
35. Venugopala KN, Chandrashekarappa S, Pillay M, et al. Synthesis and structural elucidation of novel benzothiazole derivatives as anti-tubercular agents: in-silico screening for possible target identification. *Medicinal Chem* 2019;15:311–26.
36. Chandrashekarappa S, Venugopala KN, Venugopala R, Padmashali B. Qualitative anti-tubercular activity of synthetic ethyl 7-acetyl-2-substituted-3-(4-substituted benzoyl) indolizine-1-carboxylate analogues. *J Appl Pharma Sci* 2019;9:124–8.
37. Alveera S, Venugopala KN, Khedr MA, et al. Antimycobacterial, docking and molecular dynamic studies of pentacyclic triterpenes from *Buddleja saligna* leaves. *J Biomol Struct Dyn* 2017;35:2654–64.
38. Venugopala KN, Dharma Rao GB, Bhandary S, et al. Design, synthesis, and characterization of (1-(4-aryl)-1H-1,2,3-triazol-4-yl)methyl, substituted phenyl-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylates against *Mycobacterium tuberculosis*. *Drug Design Dev Ther* 2016;10:2681–90.
39. Venugopala KN, Nayak SK, Pillay M, et al. Synthesis and anti-tubercular activity of 2-(substituted phenyl/benzyl-amino)-6-(4-chlorophenyl)-5-(methoxycarbonyl)-4-methyl-3,6-

- dihydropyrimidin-1-ium chlorides. *Chem Biol Drug Des* 2013; 81:219–27.
40. Venugopala KN, Albericio F, Coovadia YM, et al. Total synthesis of a depsidomycin analogue by convergent solid-phase peptide synthesis and macrolactonization strategy for antitubercular activity. *J Peptide Sci* 2011;17:683–9.
 41. Salgado-Moran G, Ramirez-Tagle R, Glossman-Mitnik D, et al. Docking studies of binding of ethambutol to the C-Terminal domain of the arabinosyltransferase from *Mycobacterium tuberculosis*. *J Chem* 2013;601270.
 42. Sandeep C, Venugopala KN, Gleiser RM, et al. Greener synthesis of indolizine analogues using water as a base and solvent: study for larvicidal activity against *Anopheles arabiensis*. *Chem Biol Drug Des* 2016;88:899–904.
 43. Bruker. APEX2. Madison (WI): Bruker AXS Inc.; 2012.
 44. Bruker. SAINT and SADABS. Madison (WI): Bruker AXS Inc.; 2008.
 45. Sheldrick GM. A short history of SHELX. *Acta Crystallographica Section A* 2008;64:112–22.
 46. Sheldrick G. Crystal structure refinement with SHELXL. *Acta Crystallographica Section C* 2015;71:3–8.
 47. Spek A. checkCIF validation ALERTS: what they mean and how to respond. *Acta Crystallographica Section E* 2020;76: 1–11.
 48. Farrugia L. WinGX and ORTEP for Windows: an update. *J Appl Crystallogr* 2012;45:849–54.
 49. Martin A, Morcillo N, Lemus D, et al. Multicenter study of MTT and resazurin assays for testing susceptibility to first-line anti-tuberculosis drugs. *Int J Tuberc Lung Dis* 2005;9: 901–6.
 50. Mossman T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J Immunol Meth* 1983;65:55–63.
 51. Chandrashekarappa S, Venugopala KN, Tratrak C, et al. Efficient synthesis and characterization of novel indolizines: exploration of in vitro COX-2 inhibitory activity and molecular modelling studies. *New J Chem* 2018;42:4893–901.
 52. Christophe T. Novel thiazole-based thiazolidinones as potent anti-infective agents: *in silico* PASS and toxicity prediction. *Synth Biol Eval Mol Model Combin Chem High Throughput Screen* 2020;23:126–40.
 53. Deb PK, Al-Attaqchi O, Mohammed NA-Q, et al. Applications of computers in pharmaceutical product formulation. In: Tekade RK, ed. Dosage form design considerations: advances in pharmaceutical product development and research series. Vol. II. Waltham (MA): Academic Press; 2018: 665–703.
 54. Deb PK, El-Rabie D, Ahmad J, et al. In silico binding mode analysis (molecular docking studies), and ADME prediction of some novel inhibitors of aurora kinase a in clinical trials. *Asian J Chem* 2014;26:6221–6.
 55. Chollet A, Maveyraud L, Lherbet C, Bernardes-Genisson V. An overview on crystal structures of InhA protein: Apo-form, in complex with its natural ligands and inhibitors. *Eur J Med Chem* 2018;146:318–43.
 56. Parikh S, Moynihan DP, Xiao G, Tonge PJ. Roles of tyrosine 158 and lysine 165 in the catalytic mechanism of InhA, the enoyl-ACP reductase from *Mycobacterium tuberculosis*. *BioChem* 1999;38:13623–34.
 57. Kamsri P, Hanwarinroj C, Phusi N, et al. Discovery of new and potent InhA inhibitors as antituberculosis agents: structure-based virtual screening validated by biological assays and X-ray crystallography. *J Chem Info Model* 2020;60: 226–34.
 58. Rozwarski DA, Vilchèze C, Sugantino M, et al. Crystal structure of the *Mycobacterium tuberculosis* enoyl-ACP reductase, InhA, in complex with NAD⁺ and a C16 fatty acyl substrate*. *J Biol Chem* 1999;274:15582–9.
 59. Guardia A, Gulten G, Fernandez R, et al. N-Benzyl-4-((hetero-aryl)methyl)benzamides: a new class of direct NADH-dependent 2-trans enoyl-acyl carrier protein reductase (InhA) inhibitors with antitubercular activity. *ChemMedChem* 2016;11:687–701.
 60. Martínez-Hoyos M, Perez-Herran E, Gulten G, et al. Antitubercular drugs for an old target: GSK693 as a promising InhA direct inhibitor. *EBioMedicine* 2016;8:291–301.
 61. Shirude PS, Madhavapeddi P, Naik M, et al. Methyl-thiazoles: a novel mode of inhibition with the potential to develop novel inhibitors targeting INHA in *Mycobacterium tuberculosis*. *J Med Chem* 2013;56:8533–42.
 62. Encinas L, O'Keefe H, Neu M, et al. Encoded library technology as a source of hits for the discovery and lead optimization of a potent and selective class of bactericidal direct inhibitors of *Mycobacterium tuberculosis* InhA. *J Med Chem* 2014;57:1276–88.
 63. Spagnuolo LA, Eltschkner S, Yu W, et al. Evaluating the contribution of transition-state destabilization to changes in the residence time of triazole-based InhA inhibitors. *J Am Chem Soc* 2017;139:3417–29.
 64. Mtb InhA complex with Pyridazinone compound 14. <https://www.rcsb.org/structure/4D0S> [last accessed 25 March 2021].
 65. Discovery of pyrimidine isoxazoles InhA in complex with compound 23. <https://www.rcsb.org/structure/4UVI> [last accessed 25 March 2021].